US › Healthcare

Vyne Therapeutics Inc (VYNE)

US · Healthcare · Biotechnology

$30.45+8.56%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

$86,000

Revenue YoY

-57.4%

Net profit

$-3.6M

Profit YoY

+58.4%

EPS

$-0.08

Net margin

-4,168.6%

Key statistics

Market cap

$19.1M

Forward P/E

0.0

P/B

0.75

Book value

$36.93

EPS (TTM)

$-27.58

52-week high

$46.95

52-week low

$0.16

50-day MA

$34.03

200-day MA

$28.60

Beta

2.01

Analyst view

Analysts rate Vyne Therapeutics Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $2.00.

Shareholding

Insiders

17.94%

Institutions

39.62%

Largest institutional holders

Fund	Stake
Anson Funds Management LP	1.84%
Nantahala Capital Management, LLC	1.48%
Lynx1 Capital Management, LP	1.21%
Shay Capital LLC	1.19%
ADAR1 Capital Management LLC	0.79%
T3 Companies, LLC	0.70%
BRAIDWELL LP	0.68%
Citadel Advisors Llc	0.38%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Vyne Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.